Which condition is characterized by shortened RBC lifespan with elevated erythropoietin and compensatory erythropoiesis, along with accumulation of hemoglobin degradation products?

Which condition is characterized by shortened RBC lifespan with elevated erythropoietin and compensatory erythropoiesis, along with accumulation of hemoglobin degradation products?

• A. Hemolytic anemia
• B. Aplastic anemia
• C. Iron deficiency anemia
• D. Myelodysplastic syndrome

Answer: (A)

When red cells are destroyed faster than they can be made, their lifespan is shortened and the body compensates by boosting erythropoietin production and increasing erythropoiesis in the marrow. This leads to a marked rise in reticulocytes as the bone marrow tries to replace the lost cells. The ongoing destruction also releases heme, which is degraded into hemoglobin breakdown products like bilirubin and other byproducts, causing accumulation of these degradation products in the body. This combination—shortened RBC lifespan, elevated erythropoietin, compensatory erythropoiesis, and buildup of hemoglobin degradation products—is classic for hemolytic anemia. Other anemias don’t typically show this same pattern of active destruction with a robust erythropoietic response and accumulation of hemoglobin breakdown products; for example, aplastic anemia shows inadequate production, while iron deficiency and myelodysplastic syndromes involve production defects rather than rapid destruction with elevated turnover.

When red cells are destroyed faster than they can be made, their lifespan is shortened and the body compensates by boosting erythropoietin production and increasing erythropoiesis in the marrow. This leads to a marked rise in reticulocytes as the bone marrow tries to replace the lost cells. The ongoing destruction also releases heme, which is degraded into hemoglobin breakdown products like bilirubin and other byproducts, causing accumulation of these degradation products in the body. This combination—shortened RBC lifespan, elevated erythropoietin, compensatory erythropoiesis, and buildup of hemoglobin degradation products—is classic for hemolytic anemia.

Other anemias don’t typically show this same pattern of active destruction with a robust erythropoietic response and accumulation of hemoglobin breakdown products; for example, aplastic anemia shows inadequate production, while iron deficiency and myelodysplastic syndromes involve production defects rather than rapid destruction with elevated turnover.